What the archived record actually shows about who made October pink
Credit: Daily Vitality
Sometime around the first of October, the pink arrives. It shows up on yogurt lids and cereal boxes, on the cleats of professional athletes, on the sides of buildings lit up after dark, on the little enamel pin someone hands you at the office. It is so thoroughly part of the season that it can feel like weather — something that simply happens in the fall, the way leaves turn.
It did not simply happen. Every piece of it was decided by somebody, in a specific year, for a specific reason. A month was chosen. A color was chosen, and then chosen again after the first color did not work out. A partnership was formed between a cancer charity and a drug company, and that drug company happened to make the leading breast cancer medication in the world. None of this is secret. Most of it is sitting in publicly archived web pages that almost nobody reads.
What follows is that record, laid out in order, with the dates attached. Some of it will match the version you have seen shared online. Some of it will not, and the places where it does not are the interesting part — because the popular retelling has hardened into a set of claims that the documents do not quite support. Where the evidence is thin, you will see that said plainly rather than smoothed over. This is a story about media and money, not about medicine, and it is told here without any claim about what causes breast cancer or what anyone should do about it.
The campaign's own account is the place to start, and it is more modest than you might expect. According to an archived version of the National Breast Cancer Awareness Month website captured in December 1998, "the first week-long NBCAM program took place in October 1985 with a goal to fill the information void in public communication about breast cancer." Not a month. A week.
The same page describes what that first week consisted of, and the scale is human rather than corporate. The two founding members of the campaign's Board of Sponsors handed out brochures, talked to reporters, and testified before a congressional committee about the need for wider access to mammography. Former First Lady Betty Ford, who had gone public with her own breast cancer diagnosis in 1974, appeared with her daughter Susan Ford Bales in a national public service announcement. That was the launch.
The purpose was narrow and specific from the beginning: get more women screened. The American Cancer Society, marking the campaign's fortieth anniversary, describes the founding aim in almost the same terms, as an effort to educate women about early screening and routine mammograms. The month was designed around a behavior, not around research funding — a distinction that would matter enormously later, and that critics would spend the next three decades arguing about.
If you find it strange that a disease's most famous public campaign started this small, it helps to remember how much the landscape of American mortality has shifted, and how recently — something we traced in how the leading causes of death reshuffled over 100 years.
Here is where the record gets genuinely interesting, and where it diverges from what nearly every article about October will tell you.
The standard sentence, reproduced almost word for word across encyclopedias, university pages, and health sites, is that Breast Cancer Awareness Month was established as a partnership between the American Cancer Society and the pharmaceutical division of Imperial Chemical Industries. The Breast Cancer Consortium, an academic project that studies pink ribbon culture, uses exactly that formulation, noting that ICI is now part of AstraZeneca. It is repeated by Britannica, by a Rutgers genetics center page, and by Breastcancer.org.
That account is almost certainly correct in substance. It is also, as far as this research could establish, not confirmed by any primary document from 1985 that is retrievable today. Every version traces back to the same secondary sentence. That is worth knowing before you repeat it.
What is available is stranger, and it complicates the story rather than confirming it. NBCAM's own Board of Sponsors page, captured in December 1998, lists seventeen member organizations. Two of them carry an asterisk, and the footnote at the bottom of the page reads simply: "*Founding Members." Those two are Cancer Care, Inc. and the Zeneca HealthCare Foundation.
The American Cancer Society is on that list. It does not have the asterisk.
This does not prove the American Cancer Society was uninvolved in 1985 — its own account says it co-led the effort, and that account deserves weight. But it does mean that the organization running the campaign, on its own website, for years, identified its founders as a patient-support charity and a drug company's foundation. Whatever the full story is, the tidy two-name version most of us have absorbed is not the version the campaign itself was publishing.
Almost every retelling of this story names the wrong company, and it is an easy mistake to make.
AstraZeneca did not exist in 1985. Neither did Zeneca. The corporate sequence is laid out on AstraZeneca's own published timeline: Imperial Chemical Industries was founded in the UK in 1926 and became one of Britain's largest manufacturers; in 1993, ICI demerged its pharmaceuticals business to form Zeneca Group PLC; and in 1999, Astra AB and Zeneca merged to create AstraZeneca PLC.
So the entity that co-sponsored the first Breast Cancer Awareness Month in 1985 was ICI Pharmaceuticals — a division of a British chemical conglomerate. Zeneca arrived eight years later. AstraZeneca arrived fourteen years after that. When you read that "AstraZeneca founded Breast Cancer Awareness Month," the claim is compressing three corporate identities across fourteen years into one name, and the compression is doing quiet work: it attaches a 1985 decision to a company that had no legal existence at the time.
There is an added wrinkle that the campaign created itself. The Zeneca HealthCare Foundation, marked as a founding member on that 1998 page, was not established until 1993 either. The organization named as a founder could not have been in the room.
This is the part of the story that gives the whole thing its charge, and it needs to be stated carefully.
ICI made tamoxifen. The drug was developed under the company's internal compound code ICI 46,474 and sold under the brand name Nolvadex, and the peer-reviewed history of its development — written by V. Craig Jordan, the field's principal historian of the compound — records that the first clinical trial was reported from Manchester in 1971, with approval following in the UK in 1973 and from the US Food and Drug Administration in 1977.
By 1985, then, the company helping to launch a national campaign urging American women to get screened for breast cancer was also the company selling the leading treatment for it. Both things are simply true, and they sat in the same building.
What the documents do not support is the leap that often follows. There is no evidence in the available record that anyone founded the month in order to sell a drug, and this article makes no such claim. A pharmaceutical company funding awareness of a disease it treats is an ordinary commercial arrangement, and it was more ordinary still in the mid-1980s, before disclosure norms tightened. The honest description is narrower and, in its way, more useful: the incentives were aligned, the alignment was never hidden, and almost nobody noticed.
Public understanding of cancer risk keeps moving, of course — including on the everyday levers people ask about most, like the finding that 10 minutes of hard exercise can trigger anti-cancer effects.
If you want to see the relationship rather than infer it, the campaign's own web pages are remarkably direct.
The NBCAM homepage captured in December 1998 carries a copyright line at the foot of the page reading "© Copyright 1998 Zeneca Health Care Foundation." Five years later, the same site's pages read "© Copyright 2003 AstraZeneca HealthCare Foundation" — the name updated to match the merger, the arrangement unchanged. The awareness month was not merely sponsored by a drug company's foundation. Its public face was that foundation's copyrighted property.
The 2003 Board of Sponsors page describes the AstraZeneca HealthCare Foundation as "a principal sponsor" of the program and notes, in the same entry, that the foundation "was established in 1993 as the Zeneca HealthCare Foundation."
Then there is the detail that requires no interpretation at all. Buried in the HTML of those pages — in the meta keywords, the list a site gives search engines to describe what it is about — sit the words "nolvadex, tamoxifen, zeneca, pharmaceuticals" on the 1998 homepage, and "nolvadex, tamoxifen, tamoxafen" alongside "astrazeneca" on the 2003 pages. A public health awareness campaign told search engines it was about a brand-name breast cancer drug.
Meta keywords were a routine search-optimization tool in the 1990s and early 2000s, and their presence is not evidence of a hidden intention. It is evidence of who was building the pages, and of what they considered relevant to the campaign.
The ribbon has a separate origin from the month, and a much better-documented one — though it rests almost entirely on a single piece of reporting, which is worth flagging before we go further.
In 1991, a 68-year-old woman named Charlotte Haley began making ribbon loops by hand at her dining room table in Southern California. She was, in the words of journalist Sandy M. Fernandez, "the granddaughter, sister, and mother of women who had battled breast cancer." The loops were peach.
They also came with a demand. Each set of five was accompanied by a card carrying a specific and pointed message: "The National Cancer Institute annual budget is $1.8 billion, only 5 percent goes for cancer prevention. Help us wake up our legislators and America by wearing this ribbon."
Read that again, because it is the hinge of the entire story. The first breast cancer ribbon was not an awareness symbol. It was a lobbying instrument, aimed at a line item in a federal budget, asking the people who wore it to pressure Congress about prevention spending. Awareness was not the goal. Appropriations were.
Haley worked entirely by hand and by mail — handing cards out at her local supermarket, writing letters to prominent women from former First Ladies to Dear Abby. By the time the columnist Liz Smith printed her phone number in 1992, she had distributed thousands.
One correction belongs here, because nearly every account gets it wrong. Pink was not invented in 1992. Fernandez's reporting records that the Susan G. Komen Breast Cancer Foundation had been handing out bright pink visors to survivors at its Race for the Cure since late 1990, and gave a pink ribbon to every participant in its New York City race in the fall of 1991 — before the events that follow. Pink was already in the air. What 1992 did was make it permanent.
Early in 1992, Alexandra Penney, then editor-in-chief of Self, was putting together the magazine's second annual Breast Cancer Awareness Month issue. The first, in 1991, had been guest-edited by Evelyn Lauder — a senior corporate vice president at Estée Lauder and a breast cancer survivor herself — and had done well. Penney wanted a ribbon, and wanted the cosmetics company to hand it out in New York City stores. Lauder proposed something larger: counters nationwide.
Then Liz Smith's column ran, and they learned that someone was already doing this.
Self called Haley. Penney's recollection of the offer, as she told Fernandez years later, was that the magazine said: "We want to go in with you on this, we'll give you national attention, there's nothing in it for us." Haley's answer was no. In Penney's account, "she wanted nothing to do with us. Said we were too commercial." Breast Cancer Action, the advocacy organization that later published her obituary, records the same refusal in her own framing: they were too corporate and commercial for her.
This is the beat the popular version most often mangles. Charlotte Haley was not ignored, and she was not robbed. She was approached by a national magazine and a global cosmetics company, offered a partnership, and she declined it. That was her decision, and she made it on principle.
What happened next was a legal one. Fernandez reports Penney's account of the deliberation: "We didn't want to crowd her. But we really wanted to do a ribbon. We asked our lawyers and they said, come up with another color." They chose pink. The reason the ribbon is pink rather than peach is not symbolism, or psychology, or a study about calming hues. It is that a lawyer advised a color change to avoid using a concept its creator had refused to license.
At the end of September 1992, Smith ran a follow-up column reporting that Estée Lauder had experienced "problems" working with Haley, and quoting Haley saying Self had asked her to relinquish the concept of the ribbon.
What a retail network can do that a dining room table cannot is volume.
In the fall of 1992, Estée Lauder makeup counters handed out 1.5 million pink ribbons, each with a laminated card describing a breast self-exam. They also collected more than 200,000 petitions urging the White House to increase research funding — closer to Haley's original demand than the awareness framing that would come to dominate. Within a year, as Fernandez put it, Charlotte Haley's loop of peach ribbon was history.
The Smithsonian's National Museum of American History, which has documented Evelyn Lauder's campaign, describes the method plainly: pledge cards and petitions at makeup counters, pink ribbon designs on selected products, women's purchasing power turned toward research funding. The model worked, and it was copied immediately.
It is also worth saying clearly that this produced something durable. Evelyn Lauder had been diagnosed with early-stage breast cancer herself, helped establish a breast center at Memorial Sloan Kettering in 1989, and founded the Breast Cancer Research Foundation in 1993 with the oncologist Dr. Larry Norton and her husband, Leonard Lauder. A story about commercialization that leaves this out is not a complete story.
The merchandising followed fast. In 1993 Avon launched a $2 enameled pink ribbon pin that raised $10 million in its first two years; that same October, Estée Lauder introduced a heart-shaped compact with a pink ribbon design, and Komen began selling a pink rhinestone brooch. The cause-marketing consultant Carol Cone, who helped build Avon's campaign, counted fifteen sizeable companies involved with breast cancer at the time and roughly eighty to a hundred by 1998. Her explanation of the appeal was blunt: companies want to support breast cancer, she told Fernandez, because breast cancer is safe.
Numbers like these have a way of reshaping what we assume about a disease, which is a pattern we keep running into — see 9 health statistics from 2026 that surprised even researchers.
Four corrections, each with the evidence behind it.
A fifth item is less a correction than a caution about the record itself. NBCAM's own website could not keep its history straight: the 1998 pages state that President Clinton signed legislation in 1992 proclaiming National Mammography Day, while the 2003 pages say it was first proclaimed by Clinton in 1993. The 1992 date cannot be right — Clinton did not take office until January 1993 — and the Breast Cancer Consortium dates the proclamation to the 1993 campaign.
That is a small error. But it is a small error published by the organization at the center of this story, about its own history, on its own website, and it is a good reason to treat every confident retelling of these events, including the well-meaning ones, as something to check rather than something to forward. Even careful outlets reproduce the compressed version; Breastcancer.org's account names ICI and tamoxifen accurately but does not mention Charlotte Haley at all.
Seventeen years after the first week-long campaign, the critique acquired a name.
Breast Cancer Action, a San Francisco advocacy organization, says it coined the term "pinkwashing" in 2002 and launched its Think Before You Pink campaign the same year, in response to how many pink ribbon products had appeared on the market. The organization defines a pinkwasher as a company that "claims to care about breast cancer by promoting a pink ribbon product, but at the same time produces, manufactures and/or sells products containing chemicals that are linked to the disease."
That definition contains a scientific claim about chemical exposure and breast cancer risk. It is reported here as Breast Cancer Action's stated position, because that is what it is, and this article does not attempt to settle it. What is not in dispute is the organization's narrower ask: more transparency about how much of a pink purchase reaches research, and more willingness among consumers to ask the question at all.
Which brings the story back around to a dining room table in 1991, and a card that asked people to think about a budget line rather than a symbol. The pink ribbon has since funded a great deal of real research, and the awareness campaign has almost certainly sent women for screening who would not otherwise have gone. Both of those things are worth something. So is knowing that the color on the yogurt lid was picked by a lawyer, that the month began as a week, and that the woman who made the first ribbon looked at the whole apparatus taking shape around her and decided she wanted no part of it.
None of that has to change what you do this October. It might change what you see.
If you are curious about where the current evidence sits on breast cancer specifically, rather than on the history of its symbol, our report on a study suggesting coffee may lower breast cancer death and recurrence risk is a reasonable place to start.
About the Author
Angela Nightingale
October 1985, and it ran for one week rather than the full month. The campaign's own archived website states that the first week-long program took place in October 1985, and a 2003 version of the site confirms the date by noting the campaign was then celebrating eighteen years.
Yes. The widely reproduced account is that the American Cancer Society partnered with the pharmaceutical division of Imperial Chemical Industries, and the campaign's own website listed the Zeneca HealthCare Foundation — the successor to ICI's pharmaceutical business — as a founding member. The site's copyright line named that foundation for years.
Not in 1985. AstraZeneca was created in 1999 when Astra AB merged with Zeneca, and Zeneca itself was only formed in 1993 when ICI spun off its pharmaceuticals business. The company involved at the founding was ICI Pharmaceuticals. Naming AstraZeneca as the 1985 founder collapses fourteen years of corporate history into one label.
Tamoxifen, developed under the compound code ICI 46,474 and sold as Nolvadex. It was first trialed clinically in 1971 and approved in the United States in 1977, which means the company was selling the leading breast cancer treatment well before the awareness campaign began.
Charlotte Haley, who was 68 when she began making peach-colored loops by hand in 1991. Her ribbons came with a card noting that only 5 percent of the National Cancer Institute's $1.8 billion budget went to prevention, and asking wearers to press legislators about it.
Because lawyers advised a color change. After Haley declined to work with Self magazine and Estée Lauder, the magazine's editor recalled being told by counsel to come up with another color. They chose pink. The switch was a legal workaround, not a symbolic decision.
The documented sequence is more specific than that. She was approached, offered national partnership, and refused because she found the companies too commercial. The ribbon concept was then reworked in a different color so that her permission was not required. She was neither ignored nor overruled — she said no, and the project went around her.
Retail distribution. In the fall of 1992, Estée Lauder counters handed out 1.5 million pink ribbons with breast self-exam cards and collected over 200,000 petitions for research funding. Merchandising followed within a year, including Avon's $2 enamel pin, which raised $10 million in its first two years.
Breast Cancer Action says it coined the term in 2002, alongside its Think Before You Pink campaign. The organization uses it for companies that promote a pink ribbon product while also selling products containing chemicals it says are linked to the disease. That chemical claim is the organization's stated position and is not evaluated here.
The 1985 founding date, the corporate lineage and the campaign's sponsorship are documented in dated primary sources. The Haley sequence rests largely on one piece of reporting — Sandy M. Fernandez's article in MAMM magazine in 1998 — and Fernandez noted at the time that Estée Lauder and the Breast Cancer Research Foundation did not respond to repeated interview requests. The account is credible and widely relied upon, but it is one account.
